Targeted drug shows promise in advanced kidney cancer

Singles out abnormal blood vessel formation that fuels tumor growth Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma in patients with metastatic disease. Researchers from Dana-Farber Cancer Institute report a response rate of 24 percent across all risk categories of patients given an oral first-in-class agent that targets hypoxiaContinue reading “Targeted drug shows promise in advanced kidney cancer”